This report discusses the relationship between TB and sustainable development, and advocates for increased dialogue and action among TB partners.
This book presents five papers that were used as background to a workshop on "Improving TB Drug Management: Accelerating DOTS Expansion" on June 2002, in Washington, DC. The papers address the weaknesses in drug management programs of certain countries and provide a framework for strengthening these programs through country-specific action plans.
This report provides suggestions that may facilitate increased involvement of the National Tuberculosis Control Program (NTP) in health sector reform, encourage increased technical input into health systems' planning, and promote the strategic positioning of TB control in the context of changing health systems.
This guideline promotes collaboration between TB and HIV/AIDS programs to reduce the burden for people affected by both diseases.
This report assesses the effectiveness, cost, and cost-effectiveness of the public-private mix DOTS (PPM-DOTS) program in pilot projects in Hyderabad and Delhi, India.
This report discusses compounds with potential for the treatment of TB and categorizes them into the discovery, preclinical, or clinical phases of development.
This guideline sets forth the framework to guide European countries in developing their national plan for reducing TB/HIV morbidity and mortality. The framework sets out the rationale for effective collaboration between HIV/AIDS and tuberculosis national programs.
This group of four fact sheets explain the origin and purpose of the Global Drug Facility (GDF), how the GDF works, how to apply to the GDF for a grant of TB drugs, and how to buy drugs through the GDF.
This booklet answers questions about the 4-drug fixed-dose combinations containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol that were added to the WHO Model List of Essential Drugs for the treatment of TB.
This fact sheet explains the purpose of the Global Drug Facility (GDF) to expand access to, and availability of, high-quality TB drugs to facilitate DOTS expansion, and to enable governments and nongovernmental organizations (NGOs) to implement effective TB control programs based upon the DOTS stragegy.
